Portuguese defender invests more than €1 million in personalized supplements company already backed by Cristiano Ronaldo.
Manchester United and Portugal soccer star Diogo Dalot has invested over €1 million in Bioniq, a company specializing in personalized nutritional supplements based on blood biomarker data. Dalot follows Portugal teammate Cristiano Ronaldo, who invested in the company last year, and is reflective of a growing interest in personalized health optimization among elite athletes.
Dalot has been a Bioniq customer for several years, incorporating the company’s supplements into his daily routine to enhance his health and athletic performance, with a regimen designed to reduce inflammation, increase resilience, and improve endurance.
“When it comes to high-level performance, my biggest focus has always been finding that extra 1% — the key to setting myself apart from the rest,” said Dalot, describing his experience using Bioniq as a “game-changer”.
Diogo Dalot plays at right back for Manchester United and the Portugal national team.
“I’ve seen the results for myself. Achieving such progress is only possible with a product that’s truly personalized and tailored specifically to my needs. Now, I’m thrilled to take the next step as an investor.”
As with Ronaldo, Dalot’s involvement with Bioniq will extend beyond financial backing, and he will actively collaborate with the company on product development by contributing his insights as a professional athlete.
“Diogo has an exceptional approach to performance optimization and recovery, constantly seeking the most effective and scientifically backed methods to enhance his physical and cognitive capabilities,” said Vadim Fedotov, Founder and CEO of Bioniq.
London-based Bioniq has positioned itself at the forefront of personalized supplementation by leveraging an AI-driven, blood-based analysis to address individual nutrient deficiencies. Initially developed to enhance the physical and cognitive performance of elite athletes, Bioniq’s products are now available to consumers around the world. The company has developed a proprietary biochemical database with blood test data from customers across five continents, and says it has now created custom formulas for more than 300,000 users.
Dalot with Bioniq founder Vadim Fedotov.
When we interviewed Fedotov last year, he explained that longevity and healthspan are at the core of the company’s approach.
“Longevity is all about how long you can support your body to renew its cells, to not age and not die,” he told us. “If we can help you reduce the number of sick days per year by optimizing micronutrient levels, then your body can support more growth of new cells instead of fighting illness.”
Last year, Bioniq raised $15 million in a Series B funding round, which the company claims it used to grow its customer base more than tenfold in 2024.
READ MORE: Our exclusive interview with Bioniq founder Vadim Fedotov
Photographs courtesy of Bioniq